p53 and MDM2 in renal cell carcinoma: Biomarkers for disease progression and future therapeutic targets?

Cancer

Volumn 116, Issue 4, 2010, Pages 780-790

  Noon, Aidan P ^a   Vlatković, Nikolina ^a   Polański, Radosław ^a   Maguire, Maria ^a   Shawki, Howida ^b   Parsons, Keith ^b   Boyd, Mark T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Murine double minute 2; p53; Renal cancer; Renal cell carcinoma

Indexed keywords

MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53;

CANCER GROWTH; CANCER SURVIVAL; HUMAN; KIDNEY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DISEASE PROGRESSION; GENES, P53; HUMANS; KIDNEY NEOPLASMS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 76249112073     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24841     Document Type: Review

References (82)

1. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, Md: National Cancer Institute. Based on the November 2008 SEER data submission; posted to the SEER website, 2009. Available at: http://info.cancerresearch.uk.org/cancerstats/types/kidney/incidence/. Accessed on June 15, 2009.
2. Cancer Research UK. UK Kidney Cancer Incidence Statistics, 2009. London, United Kingdom: Cancer Research UK; 2009.
3. Lane BR, Rini BI, Novick AC, Campbell SC. Targeted molecular therapy for renal cell carcinoma. Urology. 2007; 69:3-10.
4. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798-805.
5. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994;22:3551-3555.
6. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-1238.
7. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203-206.
8. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126-1132.
9. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 1997;11:1974-1986.
10. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299-303.
11. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000;275: 8945-8951.
12. Yang JY, Zong CS, Xia W, et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol. 2006;26:7269-7282.
13. Lu ML, Wikman F, Orntoft TF, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002;8:171-179.
14. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677-1679.
15. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004;4:793-805.
16. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol. 2005; 207:251-259.
17. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:434-444.
18. Slee EA, O'Connor DJ, Lu X. To die or not to die: how does p53 decide? Oncogene. 2004;23:2809-2818.
19. MacCallum DE, Hupp TR, Midgley CA, et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene. 1996;13:2575-2587.
20. Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet. 2004;36:147-150.
21. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res. 2004; 64:1951-1958.
22. Warburton HE, Brady M, Vlatkovic N, Linehan WM, Parsons K, Boyd MT. p53 regulation and function in renal cell carcinoma. Cancer Res. 2005;65:6498-6503.
23. Carroll VA, Ashcroft M. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res. 2008; 68:545-552.
24. Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009;18:894-900.
25. Perret AG, Clemencon A, Li G, Tostain J, Peoc'h M. Differential expression of prognostic markers in histological subtypes of papillary renal cell carcinoma. BJU Int. 2008;102:183-187.
26. Phuoc NB, Ehara H, Gotoh T, et al. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology. 2007; 69:843-848.
27. Kankuri M, Soderstrom KO, Pelliniemi TT, Vahlberg T, Pyrhonen S, Salminen E. The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res. 2006;26(5B):3825-3833.
28. Kramer BA, Gao X, Davis M, Hall M, Holzbeierlein J, Tawfik O. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. J Am Coll Surg. 2005;201:565-570.
29. Langner C, Ratschek M, Rehak P, Tsybrovskyy O, Zigeuner R. The pT1a and pT1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology? BJU Int. 2005;95:310-314.
30. Cho DS, Joo HJ, Oh DK, et al. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J. 2005;46:133-140.
31. Shvarts O, Seligson D, Lam J, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173:725-728.
32. Uzunlar AK, Sahin H, Yilmaz F, Ozekinci S. Expression of p53 oncoprotein and bcl-2 in renal cell carcinoma. Saudi Med J. 2005;26:37-41.
33. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 2004;63: 651-655.
34. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004;10:5464-5471.
35. Uchida T, Gao JP, Wang C, et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology. 2002;59:615-620.
36. Olumi AF, Weidner N, Presti JC. p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. Urol Oncol. 2001;6:63-67.
37. Ljungberg B, Bozoky B, Kovacs G, et al. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scand J Urol Nephrol. 2001;35:15-20.
38. Girgin C, Tarhan H, Hekimgil M, Sezer A, Gurel G. P53 mutations and other prognostic factors of renal cell carcinoma. Urol Int. 2001;66:78-83.
39. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res. 2000; 6:1840-1844.
40. Rioux-Leclercq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55:501-505.
41. Sejima T, Miyagawa I. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur Urol. 1999;35:242-248.
42. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology. 1998; 51: 1057-1061.
43. Sinik Z, Alkibay T, Ataoglu O, et al. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. Int J Urol. 1997;4:546-551.
44. Papadopoulos I, Rudolph P, Weichert-Jacobsen K. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma. Eur Urol. 1997;32:110-117.
45. Zhang XH, Takenaka I, Sato C, Sakamoto H. p53 and HER-2 alterations in renal cell carcinoma. Urology. 1997; 50:636-642.
46. Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer. 1997;80:1768-1775.
47. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur Urol. 1997;31:73-80.
48. Moch H, Sauter G, Gasser TC, et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res. 1997;25(suppl 1):S25-S30.
49. Hofmockel G, Wittmann A, Dammrich J, Bassukas ID. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res. 1996;16(6B):3807-3811.
50. Chemeris G, Loktinov A, Rempel A, Schwarz M, Bannasch P. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Arch. 1995;426:563-569.
51. Lipponen P, Eskelinen M, Hietala K, Syrjanen K, Gambetta RA. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma. Int J Cancer. 1994;57:275-280.
52. Kamel D, Turpeenniemi-Hujanen T, Vahakangas K, Paakko P, Soini Y. Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Histopathology. 1994;25:339-347.
53. Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer. 1994; 57:634-637.
54. Uhlman DL, Nguyen PL, Manivel JC, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst. 1994;86:1470-1475.
55. Boyd MT, Vlatkovic N. p53: a molecular marker for the detection of cancer. Expert Opin Med Diagn. 2008;2:1013-1024.
56. Anczukow O, Ware MD, Buisson M, et al. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat. 2008;29:65-73.
57. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552-2561.
58. Gad S, Lefevre SH, Khoo SK, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer. 2007;96:336-340.
59. Kawasaki T, Bilim V, Takahashi K, Tomita Y. Infrequent alteration of p53 pathway in metastatic renal cell carcinoma. Oncol Rep. 1999;6:329-333.
60. Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol. 1997;181:136-139.
61. Dahiya R, Deng G, Selph C, Carroll P, Presti J Jr. A novel p53 mutation hotspot at codon 132 (AAG→AGG) in human renal cancer. Biochem Mol Biol Int. 1998;44:407-415.
62. Dijkhuizen T, Van den Berg E, Van den Berg A, et al. Chromosomal findings and p53-mutation analysis in chromophilic renal-cell carcinomas. Int J Cancer. 1996;68:47-50.
63. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res. 1995;55:658-662.
64. Kuczyk MA, Serth J, Bokemeyer C, et al. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens. Int J Cancer. 1995;64:399-406.
65. Uchida T, Wada C, Wang C, Egawa S, Ohtani H, Koshiba K. Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. Cancer Res. 1994;54:3682-3685.
66. Kikuchi Y, Kishi T, Suzuki M, Furusato M, Aizawa S. Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas. Virchows Arch. 1994;424:229-233.
67. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol. 1994;7:766-770.
68. Reiter RE, Anglard P, Liu S, Gnarra JR, Linehan WM. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res. 1993;53:3092-3097.
69. Suzuki Y, Tamura G, Satodate R, Fujioka T. Infrequent mutation of p53 gene in human renal cell carcinoma detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res. 1992;83:233-235.
70. Torigoe S, Shuin T, Kubota Y, Horikoshi T, Danenberg K, Danenberg PV. p53 gene mutation in primary human renal cell carcinoma. Oncol Res. 1992;4:467-472.
71. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-629.
72. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233-240.
73. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994;54:794-799.
74. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13:4123-4129.
75. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-848.
76. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA. 2008;105:3933-3938.
77. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. 2005;7:547-559.
78. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
79. Guo C, Gasparian AV, Zhuang Z, et al. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene. 2009;28:1151-1161.
80. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell. 2009;15:171-183.
81. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181:1020-1027; discussion 1027.
82. Rouviere O, Bouvier R, Negrier S, Badet L, Lyonnet D. Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? Nat Clin Pract Oncol. 2006;3:200-213.